A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015).
Phase: Phase III clinical trials
Principal Investigator: Professore Filippi Andrea Riccardo
Main Facility: Radioterapia
Drug: MK-1084
Pathologies: Lung cancer
ClinicalTrials.gov: Read the details about clinical trials
This is a global, randomized, double-blind Phase 3 clinical study in patients with locally advanced, unresected Stage II–III non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation, who have not experienced disease progression following definitive platinum-based chemoradiotherapy. Participants will be randomly assigned to one of two treatment arms to compare the efficacy and safety of MK-1084 in combination with durvalumab versus standard treatment with durvalumab.
Arm A (Experimental Arm): MK-1084 administered orally once daily for up to 3 years in combination with durvalumab administered intravenously every 4 weeks for up to 12 months. MK-1084 is a novel, selective oral inhibitor of the KRAS G12C mutation, designed to block a molecular target involved in the growth and survival of tumor cells.
Arm B (Control Arm): Placebo for MK-1084 in combination with durvalumab administered according to the same treatment schedule as the experimental arm.
The study aims to evaluate the efficacy and safety of MK-1084 in combination with durvalumab compared with placebo plus durvalumab. The primary objective is to determine whether the addition of MK-1084 improves progression-free survival (PFS) compared with durvalumab alone.
Last update: 06/10/2026